Innate Immunotherapeutics Ltd Share Price Australian S.E.
Equities
AU000000IIL6
Biotechnology & Medical Research
Sales 2022 | 1.98M 1.3M 109M | Sales 2023 | 1.19M 782K 65.17M | Capitalization | 16.49M 10.84M 904M |
---|---|---|---|---|---|
Net income 2022 | -3M -1.97M -164M | Net income 2023 | -6M -3.94M -329M | EV / Sales 2022 | 7.87 x |
Net cash position 2022 | 12.51M 8.22M 685M | Net cash position 2023 | 6.98M 4.59M 382M | EV / Sales 2023 | 7.99 x |
P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-2.64
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.95% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 31/00/31 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 25/23/25 |
Rhiannon Jones
COO | Chief Operating Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 11/13/11 |
Robert Peach
BRD | Director/Board Member | 68 | 02/15/02 |
Warwick Tong
CHM | Chairman | - | 04/18/04 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+6.87% | 23.07B | |
-12.60% | 22.23B | |
-7.15% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |